Sugi Predict

Sugi Predict / Compounds / SCHEMBL101871

SCHEMBL101871

SCHEMBL101871

Cc1ccc(Cl)c2sc(N)nc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ HTT P42858 1/20 0.49
▸ MAPT P10636 6/20 0.46
▸ TP53 P04637 4/20 0.46
▸ LMNA P02545 5/20 0.44
▸ POLB P06746 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ PDE10A Q9Y233 1/20 0.44
▸ CASP3 P42574 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ ILK Q13418 1/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ TSHR P16473 2/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10589885 0.85 SMN1; SMN2 (0.72) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL6664363 0.84 SMN1; SMN2 (1.00) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL106320 0.84 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1HTTMAPTTP53
SCHEMBL25167805 0.81 SMN1; SMN2 (0.72) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL29860492 0.81 SMN1; SMN2 (0.72) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL12584953 0.81 MEN1 (0.51) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2035753 0.81 MEN1 (0.51) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL11119041 0.78 MEN1 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL21591736 0.78 SMN1; SMN2 (0.72) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL21099719 0.78 SMN1; SMN2 (0.72) SMN1; SMN2MEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 — — CN disclosed
EP-3623369-B1 NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
CN-115232144-A Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-10-25 — — CN disclosed
WO-2022148422-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEIGENE, LTD. (KY) 2022-07-14 — — WO disclosed
US-8883826-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-11-11 — — US disclosed
US-8674106-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-03-18 — — US disclosed
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-07-11 — — US disclosed
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2012-11-01 — — US disclosed
EP-2426115-A2 Alkynyl derivatives as modulators of metabotropic glutamate receptors Addex Pharma SA (CH) 2012-03-07 — — EP disclosed
US-7968567-B2 Compounds for the modulation of PPARγ activity AMGEN INC. (US) 2011-06-28 — — US disclosed
US-6770648-B2 ANTIDIABETIC AGENTS TULARIK INC. 2004-08-03 — — US disclosed
EP-1416931-A1 INHIBITORS OF POLYQ-AGGREGATION Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2004-05-12 — — EP disclosed
US-20030139390-A1 Compounds for the modulation of PPARgamma activity TULARIK INC. 2003-07-24 — — US disclosed
WO-2003015772-A1 INHIBITORS OF POLYQ-AGGREGATION MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-02-27 — — WO disclosed
CN-1368961-A Compounds that modulate PPAR γ activity TULARIK INC (US) 2002-09-11 — — CN disclosed
EP-1192137-A1 COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY Tularik Inc. (US) 2002-04-03 — — EP disclosed
WO-2001000579-A1 COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY TULARIK INC. (US) 2001-01-04 — — WO disclosed
EP-0039483-B1 PROCESS FOR THE PREPARATION OF 2-HYDROXY-BENZOTHIAZOLES HOECHST AKTIENGESELLSCHAFT (DE) 1984-11-21 — — EP disclosed
US-4370483-A ACIDIFICATION TO EFFECT CYCLIZATION OF AN O-MERCAPTO-N-PHENYLUREA OBTAINED BY HYDROLYSIS OF A 2-HYDROXYBENZOTHIAZOLE HOECHST AKTIENGESELLSCHAFT (DE) 1983-01-25 — — US disclosed
EP-0039483-A1 Process for the preparation of 2-hydroxy-benzothiazoles HOECHST AKTIENGESELLSCHAFT (DE) 1981-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 SMN1; SMN2 881/4885MEN1 4118/4885KMT2A 2181/4885
US-20030139390-A1 Compounds for the modulation of PPARgamma activity PPARG, PPARA, PPARD SMN1; SMN2 4237/4885MEN1 4867/4885KMT2A 4027/4885
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 SMN1; SMN2 881/4885MEN1 4118/4885KMT2A 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.